S and clinicopathological parameters. Table VI presents the methylation status ofONCOLOGY LETTERS 12: 5145-5155,Table III. Diagnostic overall performance of candidate genes. Gene BRCA1 GSTP1 P16INK4A MGMT PTEN RAR2 CCND2 BC pos./total 17/70 22/70 28/70 19/70 34/70 39/70 47/70 BBD pos./total 0/20 0/20 4/20 5/20 8/20 8/20 9/20 Sensitivity 24.3 31.4 40.0 27.1 48.six 55.7 67.1 Specificity one hundred.0 100.0 80.0 75.0 60.0 60.0 55.0 AUC 0.621 0.657 0.600 0.511 0.543 0.579 0.611 95 CI 0.497-0.745 0.540-0.775 0.465-0.735 0.367-0.654 0.400-0.686 0.437-0.720 0.468-0.754 Pvalue 0.099 0.033 0.174 0.884 0.560 0.286 0.BC, breast cancer; BBD, benign breast disease; AUC, location below the curve; CI, self-confidence interval; pos., good; BRCA1, breast cancer 1, early onset; DNA repair associated; GSTP1, glutathione S-transferase pi 1; P16INK4A, cyclin dependent kinase inhibitor 2A; MGMT, O-6methylguanine-DNA methyltransferase; PTEN, phosphatase and tensin homolog; RAR2, retinoic acid receptor beta two; CCND2, cyclin D2.Table IV. Combination of BRCA1 and GSTP1 for the diagnosis of breast cancer. Cutpoint 0 1 two LR, likelihood ratio.Sensitivity 100.0 44.3 11.four 0.Specificity 0.0 100.0 one hundred.0 100.Properly classified 77.8 56.7 31.1 22.LR+ 1.00 -LR 0.56 0.89 1.Table V. Mixture of seven candidate genes for the diagnosis of breast cancer. Cutpoint 0 1 2 3 four five six LR, likelihood ratio.Sensitivity one hundred.0 94.three 82.9 58.six 38.six 14.3 5.7 0.Specificity 0.0 ten.0 45.0 80.0 95.0 100.0 100.0 one hundred.Appropriately classified 77.8 75.six 74.4 63.three 51.1 33.3 26.7 22.LR+ 1.00 1.05 1.51 two.93 7.71 -LR 0.57 0.38 0.52 0.65 0.86 0.94 1.patients incorporated in the present study stratified by age, tumor size, histologic type, clinical stage, lymph node metastases, menopausal status plus the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal development issue receptor 2 (HER2) and P53 in cancerous tissues.ANGPTL2/Angiopoietin-like 2, Human (Biotinylated, HEK293, His-Avi) Hypermethylation of BRCA1 was demonstrated to become significantly much more frequent in sufferers with lymph node metastasis (P=0.Hepcidin/HAMP, Human (GST) 025).PMID:25147652 Hypermethylation of P16 INK4A was drastically linked with age (P= 0.015), menopausal status (P= 0.003) and P53 expression (P= 0.011). Hypermethylation of PTEN was substantially related with menopausal status (P=0.027).RAR two hypermethylation was considerably a lot more widespread in ER-negative (P= 0.002), PR-negative (P0.001) and P53-positive tumors (P=0.020). Association bet ween gene methylation and protein expression. Immunohistochemical evaluation was performed to assess the expression of BRCA1 and GSTP1. With the improve of methylation frequency, protein expression decreased considerably (P0.05; Table VII). Immunohistochemical staining outcomes collectively together with the promoter methylation status of BRCA1 and GSTP1 are shown in Fig. three.Table VI. Correlation of DNA methylation and clinicopathological parameters.Qualities 8 (22.9) 27 (77.1) 9 (25.7) 26 (74.three) 9 (25.7) 26 (74.three) 14 (40.0) 21 (60.0) 19 (54.3) 16 (45.7) ten (28.six) 25 (71.4) 0.122 0.015 0.788 six (33.three) 12 (66.7) 8 (44.four) ten (55.six) 6 (33.3) 12 (66.7) 16 (30.8) 36 (69.2) 20 (38.5) 32 (61.5) 13 (25.0) 39 (75.0) 0.840 0.655 0.N BRCA1 GSTP1 P16INK4A MGMT PTEN RAR2 CCND2 ————————————– ———————————– ———————————– ————————————- ———————————– ———————————- ————————————M U M U M U M U M U M U M U 14 (40.0) 21 (60.0) 19 (54.3) 16 (45.7.